Are you Dr. Carey?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5052 W 4th St
Hattiesburg, MS 39402Phone+1 601-261-2587Fax+1 601-264-7426
Summary
- Dr. Thomas Carey, MD is a board certified pathologist in Hattiesburg, Mississippi. He is currently licensed to practice medicine in Mississippi, Montana, and Ohio.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Pathology-Anatomic and Clinical, 1998 - 2000
Baptist Medical CenterResidency, Anatomic and Clinical Pathology, 1995 - 1996
Cleveland Clinic FoundationResidency, Pathology-Anatomic and Clinical, 1990 - 1995
Louisiana State University School of Medicine in New OrleansClass of 1990
Certifications & Licensure
MS State Medical License 2017 - 2025
OH State Medical License 1996 - 2023
MT State Medical License 2000 - 2021
LA State Medical License 1990 - 2001- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 7 citationsNuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma.Giovanni Almadori, Antonella Coli, Eugenio De Corso, Dario Antonio Mele, Stefano Settimi
Journal of Translational Medicine. 2021-09-27 - 3 citationsSlc44a2 deletion alters tetraspanin and N-cadherin expression: Reduced adhesion and enhanced proliferation in cultured mesenchymal lung cellsThankam S. Nair, Bala Naveen Kakaraparthi, Lucy Yang, Lillian Lu, Trey B. Thomas
Tissue & Cell. 2021-07-26 - 9 citationsSearcHPV: A novel approach to identify and assemble human papillomavirus-host genomic integration events in cancer.Lisa M. Pinatti, Wenjin Gu, Yifan Wang, Ahmed Elhossiny, Apurva D. Bhangale
Cancer. 2021-06-23
Press Mentions
This Shot Helps Prevent Cancer. Why Do so Few Men Get It?September 16th, 2021
MDM2-Dependent Sirt1 Degradation Is a Prerequisite for Sirt6-Mediated Cell Death in Head and Neck CancersMarch 16th, 2021
Grant Support
- Biomarkers To Guide Treatment And Improve Survival In Oral/Oropharyngeal CancerNational Institute Of Dental &Craniofacial Research2009–2012
- C3: Tissue And HistopathologyNational Cancer Institute2008–2011
- Defining Antigenic Targets Of Autoimmune Sensorineural Hearing LossNational Institute On Deafness And Other Communication Disorders2006–2011
- Antigenic Targets Autoimmune Sensorineural Hearing LossNational Institute On Deafness And Other Communication Disorders1999–2003
- Predicting Response To Therapy: Detection Of Oral CancerNational Institute Of Dental &Craniofacial Research1999–2003
- Galanin /Galanin Receptors--Markers Of Tumor ProgressionNational Cancer Institute2002
- Chromosome 18 Tumor Suppressor Genes In Oral CancerNational Institute Of Dental &Craniofacial Research1998–2002
- Gene Expression In Auditory Hair CellsNational Center For Research Resources1996–2000
- Antibody Induced Hearing Loss--Model For Immune DeafnessNational Institute On Deafness And Other Communication Disorders1995–1999
- Human Squamous Cell Carcinoma: Culture And SerologyNational Cancer Institute1985–1987
- Monoclonal Antibodies To Human Squamous Cancer AntigensNational Cancer Institute1985–1986
